131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA
Announces Pricing of Underwritten Offering
Option Repricing Approved for Alector, Inc. Employees
Enters Global License Agreement for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
Reports Second Quarter 2026 Financial Results and Provides Business Update
Termination of GSK Agreement for Progranulin-Elevating Antibodies
Alector, Inc. Annual Meeting Results; Class II Directors Elected
Reports First Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. Enters $125 Million Sales Agreement with TD Cowen
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
Definitive Revised Proxy Statement